Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369559 | 0.96 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL9806691 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL670857 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL10850510 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL3683207 | 0.92 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL374081 | 0.91 | OPRM1 (0.41) | SMN1; SMN2MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL713102 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL1152835 | 0.85 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL16086404 | 0.84 | TSHR (0.37) | SMN1; SMN2MEN1KMT2AKCNH2ALDH1A1 | |
| SCHEMBL5787834 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1KMT2AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049093-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORP (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4648799-A1 | LIGAND-DRUG CONJUGATES | Sun Pharma Advanced Research Company Ltd (IN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| EP-4637833-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | Genentech, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| EP-4588934-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BicycleTX Limited (GB) | 2025-07-23 | — | — | EP | disclosed |
| CN-120157682-A | Deuterated heterocyclic compounds as PDE4B inhibitors and uses thereof | 武汉人福创新药物研发中心有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-116354923-B | Nitrogen-containing heterocyclic compound and application thereof | 江苏恩华药业股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250135059-A1 | COMPOSITIONS COMPRISING FRAGRANCE MATERIALS | THE PROCTER & GAMBLE COMPANY | 2025-05-01 | — | — | US | disclosed |
| EP-0807630-A1 | HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0806418-A2 | Novel pyrimidine compound and anti-rotavirus agent | NIPPON SHOJI KAISHA, LIMITED (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-5587386-A | BACTERICIDES, MICROBIOCIDES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| EP-0640594-A1 | Hydantoin derivative as metalloprotease inhibitor | FUJIREBIO INC. (JP) | 1995-03-01 | — | — | EP | disclosed |
| EP-0275559-B1 | PLATINUM CYTOSTATIC AGENT | LACHEMA, n.p. (CS) | 1991-06-26 | — | — | EP | disclosed |
| US-4876279-A | Antihypercholesterolemic compounds | MERCK & CO., INC. (US) | 1989-10-24 | — | — | US | disclosed |
| US-4766145-A | Antihypercholesterolemic compounds | MERCK & CO., INC. (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0275559-A1 | Platinum cytostatic agent | LACHEMA, n.p. (CS) | 1988-07-27 | — | — | EP | disclosed |
| CN-87103552-A | Adopt malonate derivative to improve crop yield | — | 1988-07-06 | — | — | CN | disclosed |
| EP-0245004-A2 | Antihypercholesterolemic compounds | MERCK & CO. INC. (US) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049093-A1 | Bicyclic Ureas As Kinase Inhibitors | OXSR1, JAK1, NCOR1 | SMN1; SMN2 1686/4885MEN1 2881/4885KMT2A 2359/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | SMN1; SMN2 782/4885MEN1 2259/4885KMT2A 3318/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | SMN1; SMN2 787/4885MEN1 2268/4885KMT2A 3301/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | SMN1; SMN2 782/4885MEN1 2259/4885KMT2A 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.